We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ZTO Express Lies Low on Multiple Headwinds: Time to Dump?
Read MoreHide Full Article
We recently issued an updated research report on ZTO Express (Cayman) (ZTO - Free Report) . The stock has been downgraded to a Zacks Rank #5 (Strong Sell) from a Zacks Rank #3 (Hold). Going by the proven Zacks model, the Sell-rated stocks (#4 or 5) are likely to underperform the broader market over the next one to three months.
Reasons for the Downgrade
High-operating expenses have been hurting the bottom period, total operating expenses at this China-based company surged 49.7% to RMB 499.7 million.
Higher selling, general and administrative (SG&A) expenses induced a rise in the operating expenses. Apart from other factors, increase in salary and accrued bonus escalated SG&A expenses during the reported quarter.
We are also concerned about the company’s gross margin contraction in the first quarter of 2019. The metric declined to 27.5% in the quarter under review from 29.1% a year ago. This downside was due to expansion in parcel volumes and cost productivity gain. In fact, the company delivered lower-than-expected earnings per share in the period under consideration.
Moreover, the company’s business suffers stringent government regulations and strict policies of the Chinese market. Additionally, the domestic express delivery market is highly competitive due to the presence of big players like SF Express and STO Express.
The bearish sentiments revolving around the stock can be further gauged from the Zacks Consensus Estimate being revised 8.3% downward in the last 60 days for current-year earnings. Moreover, shares of this China-based company have declined 8.4% over the past three months against its industry’s rise of 3.3%.
Three-Month Price Performance
The company’s Momentum Score of D highlights its stock’s short-term unattractiveness.
Shares of SkyWest have surged more than 34% so far this year. Meanwhile, both GATX and Trinity boast an encouraging earnings history. While GATX outpaced the Zacks Consensus Estimate in each of the trailing four quarters, Trinity surpassed estimates in three of the previous four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
ZTO Express Lies Low on Multiple Headwinds: Time to Dump?
We recently issued an updated research report on ZTO Express (Cayman) (ZTO - Free Report) . The stock has been downgraded to a Zacks Rank #5 (Strong Sell) from a Zacks Rank #3 (Hold). Going by the proven Zacks model, the Sell-rated stocks (#4 or 5) are likely to underperform the broader market over the next one to three months.
Reasons for the Downgrade
High-operating expenses have been hurting the bottom period, total operating expenses at this China-based company surged 49.7% to RMB 499.7 million.
Higher selling, general and administrative (SG&A) expenses induced a rise in the operating expenses. Apart from other factors, increase in salary and accrued bonus escalated SG&A expenses during the reported quarter.
We are also concerned about the company’s gross margin contraction in the first quarter of 2019. The metric declined to 27.5% in the quarter under review from 29.1% a year ago. This downside was due to expansion in parcel volumes and cost productivity gain. In fact, the company delivered lower-than-expected earnings per share in the period under consideration.
Moreover, the company’s business suffers stringent government regulations and strict policies of the Chinese market. Additionally, the domestic express delivery market is highly competitive due to the presence of big players like SF Express and STO Express.
The bearish sentiments revolving around the stock can be further gauged from the Zacks Consensus Estimate being revised 8.3% downward in the last 60 days for current-year earnings. Moreover, shares of this China-based company have declined 8.4% over the past three months against its industry’s rise of 3.3%.
Three-Month Price Performance
The company’s Momentum Score of D highlights its stock’s short-term unattractiveness.
Stocks to Consider
Some better-ranked stocks in the broader Transportation sector are SkyWest (SKYW - Free Report) , GATX Corporation (GATX - Free Report) and Trinity Industries (TRN - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of SkyWest have surged more than 34% so far this year. Meanwhile, both GATX and Trinity boast an encouraging earnings history. While GATX outpaced the Zacks Consensus Estimate in each of the trailing four quarters, Trinity surpassed estimates in three of the previous four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>